Cargando…

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders

SIMPLE SUMMARY: Low-dose aspirin has a preventive effect against multiple malignancies, including hepatocellular carcinoma. Whether aspirin could also ameliorate the prognosis of patients who already developed advanced cancer remains an elusive question. In the case of hepatocellular carcinoma, rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ielasi, Luca, Tovoli, Francesco, Tonnini, Matteo, Tortora, Raffaella, Magini, Giulia, Sacco, Rodolfo, Pressiani, Tiziana, Trevisani, Franco, Sansone, Vito, Marasco, Giovanni, Piscaglia, Fabio, Granito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699252/ https://www.ncbi.nlm.nih.gov/pubmed/34944996 http://dx.doi.org/10.3390/cancers13246376

Ejemplares similares

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia
por: Ielasi, Luca, et al.
Publicado: (2023)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013)

Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis
por: Tovoli, Francesco, et al.
Publicado: (2018)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
por: Cortese, Andrea, et al.
Publicado: (2023)

Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients?
por: Tovoli, Francesco, et al.
Publicado: (2022)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Hot topics in hepatocellular carcinoma
por: Ielasi, Luca, et al.
Publicado: (2019)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

Aspirin intake: Can be a confounding factor in clinical trial for periodontal disease
por: Agarwal, Ashish
Publicado: (2013)

Autoantibodies to speckled protein family in primary biliary cholangitis
por: Granito, Alessandro, et al.
Publicado: (2021)

Anti-ganglioside antibodies and celiac disease
por: Granito, Alessandro, et al.
Publicado: (2021)

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
por: Goio, Elisabetta, et al.
Publicado: (2020)

Dangers of residual confounding: a cautionary tale featuring cognitive ability, socioeconomic background, and education
por: Sorjonen, Kimmo, et al.
Publicado: (2021)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour
por: Johnston, Ron, et al.
Publicado: (2017)

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
por: Tovoli, Francesco, et al.
Publicado: (2018)

Current guidelines for the management of celiac disease: A systematic review with comparative analysis
por: Raiteri, Alberto, et al.
Publicado: (2022)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic
por: Raiteri, Alberto, et al.
Publicado: (2021)

Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke
por: Chen, Siqia, et al.
Publicado: (2017)

Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art
por: Monaco, Giovanni, et al.
Publicado: (2023)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods
por: Raiteri, Alberto, et al.
Publicado: (2022)

Population-Based Estimates of Physical Activity for Adults with Type 2 Diabetes: A Cautionary Tale of Potential Confounding by Weight Status
por: Plotnikoff, Ronald C., et al.
Publicado: (2011)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
por: Marasco, Giovanni, et al.
Publicado: (2021)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Confounding
por: Andrade, Chittaranjan
Publicado: (2007)

A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis
por: Kroesen, Vera Marie, et al.
Publicado: (2018)

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023)

Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
por: Lu, Lu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c87fbdllggfva3o6n69od347qd